Anti-IL-4/IL-13 for the treatment of asthma: the story so far

References

• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 [Article]. Lancet. 2018;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391(10122):783–800.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Gibson PG. Asthma exacerbations · 4: prevention [Review]. Thorax. 2006;61(11):992–999.
   PubMed Web of Science ®Google Scholar
• Reddel HK. Action needed on asthma plans [Editorial]. Primary Care Respir J. 2011;20(2):116–117.
   PubMedGoogle Scholar
• Ebmeier S, Thayabaran D, Braithwaite I, et al. Trends in international asthma mortality: analysis of data from the WHO mortality database from 46 countries (1993–2012) [Article]. Lancet. 2017;390(10098):935–945.
   PubMed Web of Science ®Google Scholar
• Global Initiaitve for Asthma. Difficult-to-treat & severe asthma in adolescent and adult patients. Diagnosis and management. 2019. [cited 2019 Aug]. Available from: http://ginasthma.org
   Google Scholar
• Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015 Apr;135(4):896–902.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [Article]. Eur Respir J. 2014;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: A roadmap to consensus. Eur Respir J. 2017;49(5):1700634.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies [Article]. Lancet Respir Med. 2016;4(7):549–556.
   PubMed Web of Science ®Google Scholar
• Kuruvilla ME, Lee FEH, Lee GB, et al. Endotypes, and mechanisms of disease [Review]. Clin Rev Allergy Immunol. 2019;56(2):219–233.
   PubMed Web of Science ®Google Scholar
• Corren J. Role of interleukin-13 in asthma [Article]. Curr Allergy Asthma Rep. 2013;13(5):415–420.
   PubMed Web of Science ®Google Scholar
• Parulekar AD, Kao CC, Diamant Z, et al. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. Curr Opin Pulm Med. 2018 Jan;24(1):50–55.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease [Review]. J Clin Investig. 2008;118(11):3546–3556.
   PubMed Web of Science ®Google Scholar
• Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: A novel treatment for asthma. J Asthma Allergy. 2014;7:123–130.
   PubMedGoogle Scholar
• Barranco P, Phillips-Angles E, Dominguez-Ortega J, et al. Dupilumab in the management of moderate-to-severe asthma: the data so far. Ther Clin Risk Manag. 2017;13:1139–1149.
   PubMed Web of Science ®Google Scholar
• Edris A, De Feyter S, Maes T, et al. Monoclonal antibodies in type 2 asthma: A systematic review and network meta-analysis [Review]. Respir Res. 2019;20(1):179.
   PubMed Web of Science ®Google Scholar
• Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999 Dec;160(6):1816–1823.
   PubMed Web of Science ®Google Scholar
• Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma [Article]. Clin Exp Immunol. 2002;130(1):93–100.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, phase 2b trial [Article]. Lancet Respir Med. 2015;3(9):692–701.
   PubMed Web of Science ®Google Scholar
• Panettieri RA Jr., Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials [Article]. Lancet Respir Med. 2018;6(7):511–525.
   PubMed Web of Science ®Google Scholar
• Russell RJ, Chachi L, FitzGerald JM, et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial [Article]. Lancet Respir Med. 2018;6(7):499–510.
   PubMed Web of Science ®Google Scholar
• Hua F, Ribbing J, Reinisch W, et al. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients [Article]. Br J Clin Pharmacol. 2015;80(1):101–109.
   PubMed Web of Science ®Google Scholar
• Scheerens H, Arron JR, Zheng Y, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge [Article]. Clin Exp Immunol. 2014;44(1):38–46.
   Google Scholar
• Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies [Article]. Thorax. 2015;70(8):748–756.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials [Article]. Lancet Respir Med. 2016;4(10):781–796.
   PubMed Web of Science ®Google Scholar
• Hodsman P, Ashman C, Cahn A, et al. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics [Article]. Br J Clin Pharmacol. 2013;75(1):118–128.
   PubMed Web of Science ®Google Scholar
• De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial [Article]. J Allergy Clin Immunol. 2014;133(4):989–996.e4.
   PubMed Web of Science ®Google Scholar
• Antoniu SA, Cojocaru I. Pitrakinra for asthma [Review]. Expert Opin Biol Ther. 2010;10(11):1609–1615.
   PubMed Web of Science ®Google Scholar
• Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788–796.
   PubMed Web of Science ®Google Scholar
• Kau AL, Korenblat PE. Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes. Curr Opin Allergy Clin Immunol. 2014;14(6):570–575.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Wang L, Pirozzi G, et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/mul. Am J Respir Crit Care Med. 2015;191:A6362(MeetingAbstracts).
   Google Scholar
• Wenzel SE, Teper A, Wang L, et al. ACQ5 improvement with dupilumab in patients with persistent asthma and elevated eosinophil levels: responder analysis from a 12-week proof-of-concept placebo-controlled trial. Am J Respir Crit Care Med. 2014;189:A1323(MeetingAbstracts).
   Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.
   PubMed Web of Science ®Google Scholar
• Swanson BN, Teper A, Hamilton JD, et al. Dupilumab suppresses fractional exhaled nitric oxide (FeNO) and biomarkers of type 2 inflammation in adult patients with persistent uncontrolled asthma despite use of medium-to-high dose inhaled corticosteroids plus long-acting beta-agonists (ICS/LABAS). J Allergy Clin Immunol. 2016;137(2SUPPL. 1):AB190.
   Google Scholar
• Corren J, Chanez P, Castro M, et al. Dupilumab reduces severe exacerbation-related costs among asthma patients: results from a phase 2b trial. Eur Respir J. 2016;48:PA1530(Supplement 60).
   Google Scholar
• Corren J, Castro M, Chanez P, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019;122(1):41.
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, Ford LB, et al. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Ann Allergy Asthma Immunol. 2019;123(2):222.
   PubMed Web of Science ®Google Scholar
• Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018;142(1):171.
   PubMed Web of Science ®Google Scholar
• Maspero J, Gawchik SM, Zhang B, et al. Dupilumab improves lung function and reduces severe exacerbations in patients with uncontrolled persistent asthma with and without history of atopy. Allergy: Eur J Allergy Clin Immunol. 2016;71(Supplement 102):530.
   Google Scholar
• Katelaris CH, Maspero JF, Jayawardena S, et al. Dupilumab efficacy and effect on asthma control in patients with uncontrolled persistent asthma and comorbid chronic rhinosinusitis with or without nasal polyps. Intern Med J. 2017;47(Supplement 5):22.
   Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair PK, Brusselle GG, et al. Dupilumab in patients with corticosteroid-dependent severe asthma: efficacy and safety results from the randomized, double-blind, placebo-controlled phase 3 liberty asthma venture study. Am J Respir Crit Care Med. 2018;197:A7712(MeetingAbstracts).
   Google Scholar
• Rabe KF, Brusselle G, Castro M, et al. Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in liberty asthma venture. Eur Respir J. 2018;52:PA5003(Supplement 62).
   Google Scholar
• Sher L, Rabe KR, Wolfe RN, et al. Dupilumab improved morning and evening daily asthma symptoms in patients with oral corticosteroid-dependent severe asthma in the phase 3 LIBERTY ASTHMA VENTURE study. Am J Respir Crit Care Med. 2019;199:A2669(MeetingAbstracts).
   Google Scholar
• Ford LB, Rabe KF, Wolfe RN, et al. Dupilumab improved asthma control and health-related quality of life in patients with oral corticosteroid-dependent severe asthma in the phase 3 LIBERTY ASTHMA VENTURE study. Am J Respir Crit Care Med. 2019;199:A2666(MeetingAbstracts).
   Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. A randomized, controlled phase 3 study, liberty asthma quest, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma. Am J Respir Crit Care Med. 2018;197:A7700(MeetingAbstracts).
   Google Scholar
• Castro M, Busse WW, Zhang B, et al. Dupilumab treatment produces rapid and sustained improvements in FEV1 in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study. Am J Respir Crit Care Med. 2018;197:A6163(MeetingAbstracts).
   Google Scholar
• Castro M, Rabe KF, Kraft M, et al. Dupilumab improved lung function in patients with uncontrolled, moderate-to-severe asthma. Am J Respir Crit Care Med. 2019;199:A7086(MeetingAbstracts).
   Google Scholar
• Corren J, Castro M, Guillonneau S, et al. Dupilumab produces rapid and sustained improvements in asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma from the liberty asthma quest study. Am J Respir Crit Care Med. 2018;197:A5948(MeetingAbstracts).
   Google Scholar
• Wenzel S, Pavord ID, Rabe KF, et al. Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in liberty asthma quest. Eur Respir J. 2018;52:PA5005(Supplement 62).
   Google Scholar
• Pavord ID, Ford L, Sher L, et al. Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J. 2018;52:OA1651(Supplement 62).
   Google Scholar
• Maspero J, Busse WW, Katelaris CH, et al. Dupilumab improves health related quality of life in uncontrolled, moderate-to-severe asthma patients with comorbid allergic rhinitis from the phase 3 LIBERTY ASTHMA QUEST study. Allergy: Eur J Allergy Clin Immunol. 2018;73(Supplement 105):30.
   Google Scholar
• Wenzel SE, Pavord I, Zhang B, et al. Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study liberty asthma quest. Am J Respir Crit Care Med. 2018;197:A5949(MeetingAbstracts).
   Google Scholar
• Rabe KF, Castro M, Wenzel SE, et al. Dupilumab improved lung function in patients with uncontrolled, moderate-to-severe asthma despite exacerbation events during the LIBERTY ASTHMA QUEST study. Am J Respir Crit Care Med. 2019;199:A2668(MeetingAbstracts).
   Google Scholar
• Ford L, Corren J, Kuna P, et al. Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients across prior historical exacerbation subgroups in the phase 3 LIBERTY ASTHMA QUEST study. Allergy: Eur J Allergy Clin Immunol. 2018;73(Supplement 105):464–465.
   Google Scholar
• Pavord I, Ford LB, Corren J, et al. Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-tosevere asthma patients regardless of prior exacerbation history in the phase 3 liberty asthma quest study. Thorax. 2018;73(Supplement 4):A121–A122.
   Google Scholar
• Maspero JF, Katelaris CH, Busse WW, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis [Article]. J Allergy Clin Immunol Pract. 2019;S2213-2198(19):30633-6.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Bateman ED, Castro M, et al. Dupilumab reduces severe exacerbations and improves lung function in late-onset, uncontrolled, moderate-to-severe asthma patients enrolled in the LIBERTY ASTHMA QUEST study. Am J Respir Crit Care Med. 2019;199:A2667(MeetingAbstracts).
   Google Scholar
• Pavord I, Castro M, Rabe KF, et al. Dupilumab reduces severe exacerbations and improves lung function regardless of baseline bronchodilator reversibility in patients with uncontrolled, moderate-to-severe asthma enrolled in the LIBERTY ASTHMA QUEST study. Am J Respir Crit Care Med. 2019;199:A2624(MeetingAbstracts).
   Google Scholar
• Corren J, Castro M, O’Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma [Article]. J Allergy Clin Immunol Pract. 2019;S2213-2198(19):30775.
   Web of Science ®Google Scholar
• Corren J, Bousquet J, Busse WW, et al. Dupilumab suppresses inflammatory biomarkers in asthma patients with or without allergic rhinitis: post hoc analysis of the LIBERTY ASTHMA QUEST Study. J Allergy Clin Immunol. 2019;143(2 Supplement):AB97.
   Web of Science ®Google Scholar
• Kovalenko P, Dicioccio AT, Davis JD, et al. Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4Ralpha, in atopic dermatitis patients and normal volunteers. CPT. 2016;5(11):617–624.
   Web of Science ®Google Scholar
• Sanofi-Aventis. Dupilumab solution for injection: summary of product characteristics. Paris: Sanofi-Aventis; 2019.
   Google Scholar
• Sanofi Corporation. Dupixent subcutaneous injection: japanese prescribing information. Tokyo: Sanofi Corporation; 2019.
   Google Scholar
• Anonymous. Dupilumab (Dupixent) for asthma. JAMA. 2019;321(10):1000–1001.
   PubMed Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019 Sep;181(3):459–473.
   PubMed Web of Science ®Google Scholar
• Menzella F, Montanari G, Patricelli G, et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab [Article]. Ther Clin Risk Manag. 2019;15:869–875.
   PubMed Web of Science ®Google Scholar
• Xiong XF, Zhu M, Wu HX, et al. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: A meta-analysis of randomized clinical trials [Article]. Respir Res. 2019;20(1):108.
   PubMedGoogle Scholar
• Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017 Sep 7;377(10):965–976.
   PubMed Web of Science ®Google Scholar
• McDonald VM, Fingleton J, Agusti A, et al. Treatable traits: A new paradigm for 21st century management of chronic airway diseases: treatable traits down under International Workshop report [Review]. Eur Respir J. 2019;53(5):1802058.
   Web of Science ®Google Scholar
• Kostikas K, Brindicci C, Patalano F. Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD. Curr Drug Targets. 2018;19(16):1882–1896.
   PubMed Web of Science ®Google Scholar
• Rank MA, Oppenheimer JJ. Asthma biologics: underuse, overuse, and best use? Ann Allergy Asthma Immunol. 2019;122(4):358–359.76.
   PubMed Web of Science ®Google Scholar
• Krings JG, McGregor MC, Bacharier LB, et al. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol. 2019;7(5):1379–1392.
   Web of Science ®Google Scholar
• Beck LA, Deleuran M, Guttman-Yassky E, et al. Dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid asthma requiring treatment: analysis from two pooled phase 3 trials (liberty ad solo 1&2). Allergy: Eur J Allergy Clin Immunol. 2018;73(Supplement 105):76–77.
   Google Scholar
• Prens E, De Bruin-Weller M, Ettler K, et al. Dupilumab in moderate-to-severe atopic dermatitis by history of asthma and allergic rhinitis: analysis from a 52 week randomized phase 3 trial (liberty ad chronos). Allergy: Eur J Allergy Clin Immunol. 2018;73(Supplement 105):80.
   Google Scholar
• Corren J, Castro M, Maspero JF, et al. Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in liberty asthma quest. Eur Respir J. 2018;52:PA1124(Supplement 62).
   Google Scholar
• Boguniewicz M, Thaci D, Lio PA, et al. Dupilumab improves outcomes of concurrent asthma and chronic sino-nasal conditions in patients with atopic dermatitis-a pooled analysis of four phase 3 studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFE). J Allergy Clin Immunol. 2019;143(2 Supplement):AB123.
   Web of Science ®Google Scholar
• Papi A, Swanson BN, Staudinger H, et al. Dupilumab rapidly and significantly improves lung function and decreases inflammation by 2 weeks after treatment initiation in patients with uncontrolled persistent asthma. Am J Respir Crit Care Med. 2017;195:1661–1670.
   Web of Science ®Google Scholar
• Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 2019;68(2):158–166.
   PubMedGoogle Scholar
• Pavord I, Bahmer T, Braido F, et al. Severe T2-high asthma in the biologics era: European experts’ opinion [Review]. Eur Respir Rev. 2019;28(152):190054.
   PubMed Web of Science ®Google Scholar
• Manka LA, Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol. 2018;121(4):406–413.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Biologic therapies for treatment of asthma associated with type 2 inflamation: effectiveness, value, and valuebased price benchmarks: final evidence report. Boston (MA): Institute for Clinical and Economic Review; 2018 Dec 20 [cited 2019 Aug]. Available from: https://icerreview.org/material/asthma-final-evidence-report/
   Google Scholar
• Anderson WC, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367–372.
   PubMed Web of Science ®Google Scholar
• Bel EH. Moving upstream - Anti-TSLP in persistent uncontrolled asthma [Editorial]. N Engl J Med. 2017;377(10):989–991.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma [Article]. N Engl J Med. 2017;377(10):936–946.
   PubMed Web of Science ®Google Scholar